Field effect of two commercial preparations of botulinum toxin type A: A prospective, double-blind, randomized clinical trial

Hexsel, Dóris; Brum, Cristiano; Prado, Débora Zechmeister do; Soirefmann, Mariana; Rotta, Francisco Tellechea; DalʼForno, Taciana; Rodrigues, Ticiana C.

doi:10.1016/j.jaad.2011.08.011

Cited by 47 publications

(29 citation statements)

References 29 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is likely that differences among products in these studies are influenced by the specific dose ratios used 40. In this study the field of effectiveness in the frontalis muscles at 28 and 112 days after injection of 2 botulinum toxin type As at 2-dose ratios, abobotulinumtoxinA and onabotulinumtoxinA did not differ with respect to any effects at a dose ratio of 2:1 (abobotulinumtoxinA:onabotulinumtoxinA).…”

Section: The Science Of Botulinum Toxins: Composition and Pharmacologymentioning

confidence: 64%

Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction

Boulle¹,

Fagien²,

Sommer³

et al. 2010

CIA

View full text Add to dashboard Cite

Botulinum toxin type A treatment is the foundation of minimally invasive aesthetic facial procedures. Clinicians and their patients recognize the important role, both negative and positive, that facial expression, particularly the glabellar frown lines, plays in self-perception, emotional well-being, and perception by others. This article provides up-to-date information on fundamental properties and mechanisms of action of the major approved formulations of botulinum toxin type A, summarizes recent changes in naming conventions (nonproprietary names) mandated by the United States Food and Drug Administration, and describes the reasons for these changes. The request for these changes provides recognition that formulations of botulinum toxins (eg, onabotulinumtoxinA and abobotulinumtoxinA) are not interchangeable and that dosing recommendations cannot be based on any one single conversion ratio. The extensive safety, tolerability, and efficacy data are summarized in detail, including the patient-reported outcomes that contribute to overall patient satisfaction and probability treatment continuation. Based on this in-depth review, the authors conclude that botulinum toxin type A treatment remains a cornerstone of facial aesthetic treatments, and clinicians must realize that techniques and dosing from one formulation cannot be applied to others, that each patient should undergo a full aesthetic evaluation, and that products and procedures must be selected in the context of individual needs and goals.

show abstract

Section: The Science Of Botulinum Toxins: Composition and Pharmacologymentioning

confidence: 64%

Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction

Boulle¹,

Fagien²,

Sommer³

et al. 2010

CIA

View full text Add to dashboard Cite

show abstract

“…32 Patients received a total dose of 100 units/mL ONA to the frontalis on one side of the face and were randomized to receive 200 units/mL or 250 units/mL ABO to the frontalis on the other side (2:1 or 2.5:1 dose ratio). They were also randomized to determine which side of the face would be treated with ONA.…”

Section: Definitionsmentioning

confidence: 99%

“…They were also randomized to determine which side of the face would be treated with ONA. 32 The fields of effect were measured using clinical and photographic assessments as well as the Minor’s test, and electromyography. All patients received single injections of 0.02 mL to a depth of 3 mm into exactly the same position on each side of the face.…”

Section: Definitionsmentioning

confidence: 99%

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration

Nestor

Ablon

Pickett

2017

Aesthetic Surgery Journal

View full text Add to dashboard Cite

Time to onset of response and duration of response are key measures of botulinum toxin efficacy that have a considerable influence on patient satisfaction with aesthetic treatment. However, there is no overall accepted definition of efficacy for aesthetic uses of botulinumtoxinA (BoNT-A). Mechanical methods of assessment do not lend themselves to clinical practice and clinicians rely instead on assessment scales such as the Frontalis Activity Measurement Standard, Frontalis Rating Scale, Wrinkle Severity Scale, and Subject Global Assessment Scale, but not all of these have been fully validated. Onset of activity is typically seen within 5 days of injection, but has also been recorded within 12 hours with abobotulinumtoxinA. Duration of effect is more variable, and is influenced by parameters such as muscle mass (including the effects of age and sex) and type of product used. Even when larger muscles are treated with higher doses of BoNT-A, the duration of effect is still shorter than that for smaller muscles. Muscle injection technique, including dilution of the toxin, the volume of solution injected, and the positioning of the injections, can also have an important influence on onset and duration of activity. Comparison of the efficacy of different forms of BoNT-A must be made with the full understanding that the dosing units are not equivalent. Range of equivalence studies for abobotulinumtoxinA (Azzalure; Ipsen Limited, Slough UK/Galderma, Lausanne CH/Dysport, Ipsen Biopharm Limited, Wrexham UK/Galderma LP, Fort Worth, TX) and onabotulinumtoxinA (Botox; Allergan, Parsippany, NJ) have been conducted, and results indicate that the number of units of abobotulinumtoxinA needs to be approximately twice as high as that of onabotulinumtoxinA to achieve the same effect. An appreciation of the potential influence of all of the parameters that influence onset and duration of activity of BoNT-A, along with a thorough understanding of the anatomy of the face and potency of doses, are essential to tailoring treatment to individual patient needs and expectations.

show abstract

“…: intravenous. Please observe that Dysport ® and Botox ® cannot be compared directly with respect to dosage [52]. …”

Section: Treatment Of Tetanusmentioning

confidence: 99%

“…It should be noted that the two preparations of botulinum toxin A that were used, Botox ® and Dysport ® , are not equipotent and somewhat difficult to compare [52]. …”

Section: The Use Of Botulinum Toxin Against Tetanus-induced Rigidimentioning

confidence: 99%

Tetanus: Pathophysiology, Treatment, and the Possibility of Using Botulinum Toxin against Tetanus-Induced Rigidity and Spasms

Hassel

2013

Toxins

View full text Add to dashboard Cite

Tetanus toxin, the product of Clostridium tetani, is the cause of tetanus symptoms. Tetanus toxin is taken up into terminals of lower motor neurons and transported axonally to the spinal cord and/or brainstem. Here the toxin moves trans-synaptically into inhibitory nerve terminals, where vesicular release of inhibitory neurotransmitters becomes blocked, leading to disinhibition of lower motor neurons. Muscle rigidity and spasms ensue, often manifesting as trismus/lockjaw, dysphagia, opistotonus, or rigidity and spasms of respiratory, laryngeal, and abdominal muscles, which may cause respiratory failure. Botulinum toxin, in contrast, largely remains in lower motor neuron terminals, inhibiting acetylcholine release and muscle activity. Therefore, botulinum toxin may reduce tetanus symptoms. Trismus may be treated with botulinum toxin injections into the masseter and temporalis muscles. This should probably be done early in the course of tetanus to reduce the risk of pulmonary aspiration, involuntary tongue biting, anorexia and dental caries. Other muscle groups are also amenable to botulinum toxin treatment. Six tetanus patients have been successfully treated with botulinum toxin A. This review discusses the use of botulinum toxin for tetanus in the context of the pathophysiology, symptomatology, and medical treatment of Clostridium tetani infection.

show abstract

Field effect of two commercial preparations of botulinum toxin type A: A prospective, double-blind, randomized clinical trial

Cited by 47 publications

References 29 publications

Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction

Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: A review of the science, the clinical data, and patient satisfaction

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration

Tetanus: Pathophysiology, Treatment, and the Possibility of Using Botulinum Toxin against Tetanus-Induced Rigidity and Spasms

Contact Info

Product

Resources

About